May 6, 2024 - The Company plans to initiate the Phase 1 study (OSPREY) of STK-002 for the treatment of Autosomal Dominant Optic Atrophy (ADOA) in 2024.
The treatment of Dravet syndrome a severe and progressive genetic epilepsy seems to be their primary focus.
May 6, 2024 - The Company plans to initiate the Phase 1 study...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.30 |
Change
0.025(1.97%) |
Mkt cap ! $755.3M | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.31 | $1.27 | $258.9K | 200.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3158 | $1.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.30 | 27132 | 2 |
View Market Depth
| Last trade - 16.10pm 30/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |